MRK ($83.03) is trading below its intrinsic value of $253.20, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
MRK is good value based on its earnings relative to its share price (18.25x), compared to the US market average 40.05x)
Valuation
MRK is good value based on its earnings relative to its share price (18.25x), compared to the US Drug Manufacturers - General industry average (-4.33x)
Valuation
1 of 13
MRK News
Valuation
MRK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.25x
Industry
-4.33x
Market
40.05x
MRK is good value based on its earnings relative to its share price (18.25x), compared to the US market average 40.05x)
Valuation
MRK is good value based on its earnings relative to its share price (18.25x), compared to the US Drug Manufacturers - General industry average (-4.33x)
Valuation
MRK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.2x
Industry
8.46x
Market
36.62x
MRK is good value based on its book value relative to its share price (7.2x), compared to the US market average (36.62x)
Valuation
MRK is good value based on its book value relative to its share price (7.2x), compared to the US Drug Manufacturers - General industry average (8.46x)
Valuation
MRK price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRK is poor value relative to its rate of earnings growth, measured by PEG ratio (1.56x)
Valuation
MRK's financial health
Profit margin
Revenue
$12.6B
Net Income
$2.9B
Profit Margin
23.4%
MRK's Earnings (EBIT) of $13.56B can safely cover interest payments on company debt ($28.74B)
Financials
MRK's profit margin has increased (+4%) in the last year from (20.3%) to (24.3%)
Financials
Assets to liabilities
Assets
$89.8B
Liabilities
$60.5B
Debt to equity
0.98
MRK's short-term assets ($26.58B) exceed its short-term liabilities ($20.41B)
Financials
MRK's long-term liabilities ($40.13B) exceed its short-term assets ($26.58B)
Financials
MRK's debt has increased relative to shareholder equity (2.07), over the past 5 years ago (1.22)
Financials
MRK's debt to equity ratio (2.07) is considered high
Financials
Cash flow
Operating
$2.2B
Investing
-$2.2B
Financing
-$3.9B
MRK's operating cash flow ($11.04B) is sufficient to service the company's debt ($28.74B)
Financials
Merck & Stock FAQ
What is Merck &'s quote symbol?
(NYSE: MRK) Merck & trades on the NYSE under the ticker symbol MRK. Merck & stock quotes can also be displayed as NYSE: MRK.
How much is Merck &'s stock price per share?
(NYSE: MRK) Merck & stock price per share is $83.03 today (as of Jan 8, 2021).
What is the 52 week high and low for Merck & (NYSE: MRK)?
(NYSE: MRK) Merck &'s 52-week high was $92.06, and its 52-week low was $65.25. It is currently -9.8% from its 52-week high and 27.25% from its 52-week low.
What is Merck &'s Market Cap?
(NYSE: MRK) Merck &'s market cap is $210.00B, as of Jan 16, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Merck &'s market cap is calculated by multiplying MRK's current stock price of $83.03 by MRK's total outstanding shares of 2,529,241,070.
How much is Merck & stock worth today?
(NYSE: MRK) Merck & currently has 2,529,241,070 outstanding shares. With Merck & stock trading at $83.03 per share, the total value of Merck & stock (market capitalization) is $210.00B.
Merck & stock was originally listed at a price of $53.00 in Dec 31, 1997. If you had invested in Merck & stock at $53.00, your return over the last 23 years would have been 56.66%, for an annualized return of 1.97%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.